Rhythm Pharma Q1 Revenue Jumps 84% to $60.1M on IMCIVREE Success
Summary
Rhythm Pharmaceuticals reported a robust 84% year-over-year increase in Q1 product revenue, reaching $60.11 million, primarily driven by the successful launch and continued uptake of its drug IMCIVREE for acquired hypothalamic obesity and Bardet-Biedl syndrome. This strong revenue growth builds on the positive momentum from the recent marketing authorization for IMCIVREE. While the company's Q1 net loss of $55.64 million was slightly wider than analyst expectations, the significant top-line expansion underscores the commercial success of its key product. Management also provided 2026 non-GAAP operating expense guidance of $385 million to $415 million and anticipates a Japan PMDA decision on IMCIVREE in acquired hypothalamic obesity in the second half of 2026, with European launches expected in 2027. This report indicates strong product execution and provides a clear growth trajectory for the company.
At the time of this announcement, RYTM was trading at $92.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $55.31 to $122.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.